Thyroid carcinoma is the most common endocrine malignancy in dogs. Thyroidectomy and radiation therapy control local disease, yet are not always feasible, and efficacious medical therapies need to be identified. Toceranib phosphate has been reported to provide clinical benefit (CB) in dogs with thyroid carcinoma, while its role in treatment‐naïve thyroid tumours has not been well‐described. The objective of this study was to describe the use of toceranib in the management of thyroid carcinomas in dogs in both the naïve‐disease and prior therapy‐ settings. A medical record search identified 42 dogs diagnosed with thyroid carcinoma and treated with toceranib, of which 26 and 16 dogs were in settings of naïve‐disease and after prior therapy, respectively. Twenty‐three (88.4%) and twelve (75%) dogs experienced CB in the naïve and prior therapy settings, respectively. The median [95% confidence interval] progression free interval (PFI) for dogs in the naïve and prior therapy settings were 206 [106,740] and 1015 [92,1015] days, respectively. The median overall survival time (OST) for dogs in the naïve and prior therapy settings were 563 [246,916] and 1082 [289,1894] days, respectively. Overall, the data provided no evidence for differences in overall PFI (P > .20) or OST (P = .15) between settings. However, when asymptomatic at the time of diagnosis, dogs in the naïve setting showed poorer survival prognosis (estimated hazard ratio 17.2 [1.8, 163]) relative to dogs in the prior therapy setting. This study characterizes PFI, OST and CB with minimal AE in dogs with thyroid carcinoma treated with toceranib in both the naïve and prior therapy settings.

中文翻译：

---

Toceranib 磷酸盐治疗犬甲状腺癌：42 例（2009-2018）。

甲状腺癌是犬最常见的内分泌恶性肿瘤。甲状腺切除术和放射治疗控制局部疾病，但并不总是可行的，需要确定有效的药物疗法。据报道，磷酸 Toceranib 可为患有甲状腺癌的狗提供临床益处 (CB)，但其在未治疗过的甲状腺肿瘤中的作用尚未得到很好的描述。本研究的目的是描述 toceranib 在治疗犬甲状腺癌的初始疾病和既往治疗环境中的应用。医疗记录搜索确定了 42 只被诊断患有甲状腺癌并接受 toceranib 治疗的狗，其中 26 只和 16 只狗分别处于初始疾病和既往治疗后。二十三 (88. 4%) 和 12 (75%) 只狗分别在初始和先前治疗设置中经历了 CB。在初始治疗和先前治疗设置中，狗的中位 [95% 置信区间] 无进展间隔 (PFI) 分别为 206 [106,740] 和 1015 [92,1015] 天。在初始治疗和先前治疗设置中，狗的中位总生存时间 (OST) 分别为 563 [246,916] 和 1082 [289,1894] 天。总体而言，数据没有提供总体 PFI 差异的证据（P  > .20) 或 OST ( P = .15) 之间的设置。然而，当诊断时无症状时，与先前治疗环境中的狗相比，初始环境中的狗显示出较差的生存预后（估计风险比 17.2 [1.8, 163]）。本研究对 PFI、OST 和 CB 进行了表征，并在初始和先前治疗环境中用 toceranib 治疗患有甲状腺癌的狗中具有最小 AE。